pomalidomide

Pomalidomide is an oral immunomodulatory agent and thalidomide analogue used primarily in combination with dexamethasone to treat multiple myeloma in patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and whose disease has progressed. It is also approved for the treatment of Kaposi sarcoma (both AIDS-related after failure of antiretroviral therapy and HIV-negative cases). Pomalidomide exerts its effects through several mechanisms, including direct inhibition of angiogenesis and myeloma cell growth, modulation of immune responses by enhancing T cell and natural killer (NK) cell activity, downregulation of pro-inflammatory cytokines such as TNF-alpha and IL-6, disruption of interactions between myeloma cells and bone marrow stromal cells, induction of apoptosis in tumor cells, inhibition of cereblon E3 ligase activity (its primary molecular target), transcriptional inhibition of COX2, antiangiogenic effects via modulation of chemotactic factors like VEGF and FGF2. Developed as a more potent derivative than thalidomide or lenalidomide with reduced toxicity profiles[1][2][3][5][6].

Brand names

PomalystImnovid

Other names

泊马度胺4-aminothalidomide